Compare · INGM vs WGS
INGM vs WGS
Side-by-side comparison of Ingram Micro Holding Corporation (INGM) and GeneDx Holdings Corp. (WGS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INGM and WGS operate in Retail: Computer Software & Peripheral Equipment (Technology), so they compete in similar markets.
- INGM is the larger of the two at $6.22B, about 3.0x WGS ($2.09B).
- WGS has been more active in the news (2 items in the past 4 weeks vs 1 for INGM).
- INGM has more recent analyst coverage (23 ratings vs 8 for WGS).
- Company
- Ingram Micro Holding Corporation
- GeneDx Holdings Corp.
- Price
- -
- -
- Market cap
- $6.22B
- $2.09B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Retail: Computer Software & Peripheral Equipment
- Retail: Computer Software & Peripheral Equipment
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- 2020
- News (4w)
- 1
- 2
- Recent ratings
- 23
- 8
Latest INGM
- Ingram Micro Awarded U.S. Patent Advancing Its Intelligent Operating System for the Global Technology Ecosystem
- Large owner Platinum Equity, Llc sold $53,526,375 worth of shares (1,968,750 units at $27.19) (SEC Form 4)
- Perk Brings Its Spend Platform to U.S.: NYSE Content Update
- Ingram Micro Holding Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Ingram Micro Outlines Long-term Strategy, Intelligence-led Transformation and Multi-year Financial Framework at Capital Markets Day
- Large owner Platinum Equity, Llc sold $356,842,500 worth of shares (13,125,000 units at $27.19) (SEC Form 4)
- Ingram Micro Holding Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B7 filed by Ingram Micro Holding Corporation
- SEC Form 424B7 filed by Ingram Micro Holding Corporation
- Ingram Micro Holding Corporation Announces Pricing of Secondary Offering of Common Stock by its Principal Stockholder and a Concurrent Stock Repurchase
Latest WGS
- GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
- GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
- CHIEF EXECUTIVE OFFICER Stueland Katherine converted options into 18,750 shares and sold $1,025,013 worth of shares (10,501 units at $97.61), increasing direct ownership by 8% to 115,476 units (SEC Form 4) (withholding obligation)
- CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 7,197 shares and sold $363,892 worth of shares (3,728 units at $97.61), increasing direct ownership by 8% to 44,945 units (SEC Form 4) (tax withholding)
- Director Fuchs Thomas converted options into 1,146 shares (SEC Form 4)
- CHIEF EXECUTIVE OFFICER Stueland Katherine converted options into 6,547 shares and sold $310,932 worth of shares (3,692 units at $84.22), increasing direct ownership by 3% to 107,227 units (SEC Form 4) to cover taxes
- CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 2,462 shares and sold $108,220 worth of shares (1,285 units at $84.22), increasing direct ownership by 3% to 41,476 units (SEC Form 4) to satisfy tax liability
- GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
- CHIEF FINANCIAL OFFICER Feeley Kevin converted options into 717 shares and sold $31,188 worth of shares (372 units at $83.84), increasing direct ownership by 0.86% to 40,299 units (SEC Form 4) to cover taxes
- SEC Form 144 filed by GeneDx Holdings Corp.